Edition:
India

People: ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

72.95USD
8:44pm IST
Change (% chg)

$-3.58 (-4.68%)
Prev Close
$76.53
Open
$76.14
Day's High
$77.12
Day's Low
$72.87
Volume
17,055
Avg. Vol
54,891
52-wk High
$86.67
52-wk Low
$39.83

Walsh, Patrick 

Mr. Patrick D. Walsh is Independent Director of the company. He is President & Managing Member of Diligence Team, LLC, a consulting practice he founded and is based in Durham, North Carolina. From 2015 to February 2019, Mr. Walsh was the chief executive officer of Avista Pharma, a private equity backed global provider of contract manufacturing, development and analytical testing services to pharmaceutical and biotechnology clients. Prior to Avista, from 2010 to 2014, Mr. Walsh was the chief executive officer of AAIPharma Services Corporation in Wilmington, North Carolina, a private equity backed global provider of contract manufacturing services. Mr. Walsh’s earlier career includes serving as chief executive officer of Kadmus Pharmaceuticals, Inc., in Irvine, California, and serving as president and chief operating officer of publicly-traded Gensia Sicor Pharmaceuticals, Inc. Mr. Walsh currently serves as an independent director of the Board of Directors of Avid Bioservices, a publicly-traded company based in Tustin, California and serves on its nominating committee. He is also an independent director of the Board of Directors of MedPharm LTD, a privately held company in Durham, North Carolina, and serves on its compensation committee. He is also an Operating Partner to healthcare private-equity firm Ampersand Capital, based in Wellesley, Massachusetts. Mr. Walsh is a member of the Board’s Audit and Finance and Compensation Committees. Mr. Walsh is nominated for re-election based on his 30-plus years of experience leading successful pharmaceutical manufacturing and development organizations and his significant prior experience as an independent director.

Basic Compensation

Total Annual Compensation, USD 46,304
Restricted Stock Award, USD 118,548
Long-Term Incentive Plans, USD --
All Other, USD 80,857
Fiscal Year Total, USD 245,709

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Brown

273,573

Arthur Przybyl

4,197,930

Stephen Carey

1,438,750

Robert Schrepfer

1,444,160

James Marken

1,009,590

Thomas Haughey

252,569
As Of  31 Dec 2018